CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 244 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00802854
NCT00802854N/ACompleted

Post Marketing Surveillance Study To Observe Safety And Effectiveness Of Eraxis (Registered) Iv.

Pfizer·observational·Posted Dec 5, 2008·Updated Nov 21, 2018

In Brief

An observational study for Candidemia and Other Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis). Completed, enrolled 244 participants across 10 sites.

Detailed Summary

The objective of this study is to collect the safety and efficacy data of Eraxis IV (anidulafungin) 100 mg according to Korea Ministry of Food and Drug Safety regulations.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 5, 2008
Enrollment StartMar 2, 2012
Primary CompletionMay 20, 2016
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 17.6 years ago